Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells

25 Aug 2024

Abstract excerpt

BACKGROUND AND PURPOSE: The PDE4 family is considered a prime target for therapeutic intervention in several fibro-inflammatory diseases. We have investigated the molecular mechanisms of nerandomilast (BI 1015550), a preferential PDE4B inhibitor. EXPERIMENTAL APPROACH: In addition to clinically relevant parameters of idiopathic pulmonary fibrosis (IPF; lung function measurement/high-resolution computed tomography...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Connective Tissue Growth Factor Research
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphodiesterase function and regulation

Source

Identifiers

PMID: 39183442
DOI: 10.1111/bph.17303

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cellsPMID 39183442Read ↗

Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin modelSemantic proximity Read ↗

Drug Repurposing Through a Bioinformatics Pipeline Applied on Fibrotic DiseasesSemantic proximity Read ↗

Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosisSemantic proximity Read ↗

Targeting the epithelium in pulmonary fibrosis.Semantic proximity Read ↗

A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosisSemantic proximity Read ↗

A noble TGFβ biogenesis inhibitor exhibits both potent anti-fibrotic and anti-inflammatory capabilitiesSemantic proximity Read ↗

The NDUFS1/BRK1 Axis in COPD Pathogenesis: A Multi-Omics Approach Linking Mitochondrial Dysfunction to Actin Cytoskeleton DisruptionSemantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

Identification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosisSemantic proximity Read ↗

Expression profiles of nintedanib-targeting molecules in progressive fibrotic interstitial lung diseases (non-IPF-PF) and IPFSemantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.